Journal
CHEMMEDCHEM
Volume 4, Issue 7, Pages 1095-1105Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.200900045
Keywords
Alzheimer's disease; amyloid beta; HDAC inhibition; neuroprotection; PKC activation
Categories
Funding
- National Institutes of Health [RO1AG022941, RO1AG025888]
- National Cancer Institute
- Center for Cancer Research
- Adelson Medical Research Foundation
- Burke Foundation
Ask authors/readers for more resources
Alzheimer's disease (AD) is a well-studied neurodegenerative process characterized by the presence of amyloid plaques and neurofibrillary tangles. In this study, a series of protein kinase C (PKC) activators were investigated, some of which also exhibit histone deacetylase (HDAC) inhibitory activity, under the hypothesis that such compounds might provide a new path forward in the discovery of drugs for the treatment of AD. The PKC-activating properties of these drugs were expected to enhance the alpha-secretase pathway in the processing of amyloid precursor protein (APP), while their HDAC inhibition was anticipated to confer neuroprotective activity. We found that benzolactams 9 and 11-14 caused a concentration-dependent increase in sAPP alpha, and decrease in beta-amyloid (A beta) production in the concentration range of 0.1-10 mu M, consistent with a shift of APP metabolism toward the alpha-secretase-processing pathway. Moreover, compounds 9-14 showed neuroprotective effects in the 10-20 mu M range in the homocysteate (HCA) cortical neuron model of oxidative stress. In parallel, we found that the most neuroprotective compounds caused increased levels of histone acetylation (H4), thus indicating their likely ability to inhibit HDAC activity. As the majority of the compounds studied also show nanomolar binding affinities for PKC, we conclude that it is possible to design, de novo, agents that combine both PKC-activating properties along with HDAC inhibitory properties. Such agents would be capable of modulating amyloid processing while showing neuroprotection. These findings may offer a new approach to therapies that exhibit disease-modifying effects, as opposed to symptomatic relief, in the treatment of AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available